An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds

Current Pharmaceutical Design

Volumn 10, Issue 25, 2004, Pages 3121-3130

  Colombres, Marcela ^a   Sagal, Juan Paulo ^a   Inestrosa, Nibaldo C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

AchE; Alzheimer's disease; Cholinesterase inhibitors

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AP 2238; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DICLOFENAC; DONEPEZIL; FLUOXETINE; GALANTAMINE; HUPRINE; IBUPROFEN; IBUPROFEN DERIVATIVE; IBUPROFEN OCTYL PYRIDOSTIGMINE; LADOSTIGIL; METRIFONATE; MONOAMINE OXIDASE INHIBITOR; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; NOOTROPIC AGENT; PROTEIN ANTIBODY; PROTEIN INHIBITOR; RASAGILINE; RIVASTIGMINE; RS 1259; SEROTONIN TRANSPORTER; TACRINE; UNCLASSIFIED DRUG; ZANEPEZIL;

ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITION; COMPUTER MODEL; DRUG DESIGN; DRUG STRUCTURE; ENCEPHALITIS; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HYDROLYSIS; MOLECULAR INTERACTION; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; HUMANS; NOOTROPIC AGENTS;

EID: 4544291755     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383359     Document Type: Review

References (79)

1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81 (2): 741-66.
2. Ladner CJ, Lee JM. Pharmacological drug treatment of Alzheimer disease: the cholinergic hypothesis revisited. J Neuropathol Exp Neurol 1998; 57 (8): 719-31.
3. Giacobini E. From molecular structure to Alzheimer therapy. Jpn J Pharmacol 1997; 74 (3): 225-41.
4. Giacobini E. Invited review: Cholinesterase inhibitors for Alzheimer's disease therapy: from tacrine to future applications. Neurochem Int 1998; 32 (5-6): 413-9.
5. Selkoe DJ. Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease. J Clin Invest 2002; 110 (10): 1375-81.
6. Soto C, Branes MC, Alvarez J, Inestrosa NC. Structural determinants of the Alzheimer's amyloid beta-peptide. J Neurochem 1994; 63 (4): 1191-8.
7. Robinson SR, Bishop GM, Munch G. Alzheimer vaccine: amyloid-beta on trial. Bioessays 2003; 25 (3): 283-8.
8. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 1998; 18 (9): 3213-23.
9. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron 1996; 16 (4): 881-91.
10. Reyes AE, Perez DR, Alvarez A, Garrido J, Gentry MK, Doctor BP, et al. A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme. Biochem Biophys Res Commun 1997; 232 (3): 652-5.
11. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 1997; 272 (3): 348-61.
12. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003; 24 (6): 777-87.
13. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry 2001; 40 (35): 10447-57.
14. Shin I, Silman I, Bon C, Weiner L. Liposome-catalyzed unfolding of acetylcholinesterase from Bungarus fasciatus. Biochemistry 1998; 37 (13): 4310-6.
15. Soreq H, Seidman S. Acetylcholinesterase - new roles for an old actor. Nat Rev Neurosci 2001; 2 (4): 294-302.
16. Rachinsky TL, Camp S, Li Y, Ekstrom TJ, Newton M, Taylor P. Molecular cloning of mouse acetylcholinesterase: tissue distribution of alternatively spliced mRNA species. Neuron 1990; 5 (3): 317-27.
17. Tumiatti V, Rosini M, Bartolini M, Cavalli A, Marucci G, Andrisano V, et al. Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 2. Role of the substituents on the phenyl ring and nitrogen atoms of caproctamine. J Med Chem 2003; 46 (6): 954-66.
18. Bourne Y, Taylor P, Radic Z, Marchot P. Structural insights into ligand interactions at the acetylcholinesterase peripheral anionic site. EMBO J 2003; 22 (1): 1-12.
19. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, et al. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991; 253 (5022): 872-9.
20. Greenblatt HM, Dvir H, Silman I, Sussman JL. Acetylcholinesterase: a multifaceted target for structure-based drug design of anticholinesterase agents for the treatment of Alzheimer's disease. J Mol Neurosci 2003; 20 (3): 369-83.
21. Nicolet Y, Lockridge O, Masson P, Fontecilla-Camps JC, Nachon F. Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products. J Biol Chem 2003; 278 (42): 41141-7.
22. Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S1-5.
23. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, et al. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992; 13 (6): 747-58.
24. Pang YP, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase. Steps toward novel drugs for treating Alzheimer's disease. J Biol Chem 1996; 271 (39): 23646-9.
25. Recanatini M, Cavalli A, Belluti F, Piazzi L, Rampa A, Bisi A, et al. SAR of 9-amino-1, 2, 3, 4-tetrahydroacridine-based acetylcholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J Med Chem 2000; 43 (10): 2007-18.
26. Savini L, Gaeta A, Fattorusso C, Catalanotti B, Campiani G, Chiasserini L, et al. Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J Med Chem 2003; 46 (1): 1-4.
27. Weinstock M. The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. Neurodegeneration 1995; 4 (4): 349-56.
28. Jones RW. Have cholinergic therapies reached their clinical boundary in Alzheimer's disease? Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S7-S13.
29. Kryger G, Silman I, Sussman JL. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure Fold Des 1999; 7 (3): 297-307.
30. Kosasa T, Kuriya Y, Yamanishi Y. Effect of donepezil hydrochloride (E2020) on extracellular acetylcholine concentration in the cerebral cortex of rats. Jpn J Pharmacol 1999; 81 (2): 216-22.
31. Williams BR, Nazarians A, Gill MA. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 2003; 25 (6): 1634-53.
32. Bar-On P, Millard CB, Harel M, Dvir H, Enz A, Sussman JL, et al. Kinetic and structural studies on the interaction of cholinesterases with the anti-Alzheimer drug rivastigmine. Biochemistry 2002; 41 (11): 3555-64.
33. van Gool WA, Eikelenboom P. The two faces of Alzheimer's disease. J Neurol 2000; 247 (7): 500-5.
34. Piazzi L, Rampa A, Bisi A, Gobbi S, Belluti F, Cavalli A, et al. 3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6, 7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. J Med Chem 2003; 46 (12): 2279-82.
35. Bruhlmann C, Ooms F, Carrupt PA, Testa B, Catto M, Leonetti F, et al. Coumarins derivatives as dual inhibitors of acetylcholinesterase and monoamine oxidase. J Med Chem 2001; 44 (19): 3195-8.
36. De Ferrari GV, Mallender WD, Inestrosa NC, Rosenberry TL. Thioflavin T is a fluorescent probe of the acetylcholinesterase peripheral site that reveals conformational interactions between the peripheral and acylation sites. J Biol Chem 2001; 276 (26): 23282-7.
37. Reiner E, Krauthacker B, Simeon V, Skrinjaric-Spoljar M. Mechanism of inhibition in vitro of mammalian acetylcholinesterase and cholinesterase in solutions of O, O-dimethyl 2, 2, 2-trichloro-1-hydroxyethyl phosphonate (Trichlorphon). Biochem Pharmacol 1975; 24 (6): 717-22.
38. Ikonen S, Schmidt BH, Riekkinen P, Jr. Characterization of learning and memory behaviours and the effects of metrifonate in the C57BL strain of mice. Eur J Pharmacol 1999; 372 (2): 117-26.
39. Kronforst-Collins MA, Moriearty PL, Schmidt B, Disterhoft JF. Metrifonate improves associative learning and retention in aging rabbits. Behav Neurosci 1997; 111 (5): 1031-40.
40. Cummings JL, Cyrus PA, Bieber F, Mas J, Orazem J, Gulanski B. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 1998; 50 (5): 1214-21.
41. Farlow MR, Cyrus PA. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dement Geriatr Cogn Disord 2000; 11 (4): 202-11.
42. Rakonczay Z, Papp H. Effects of chronic metrifonate treatment on cholinergic enzymes and the blood-brain barrier. Neurochem Int 2001; 39 (1): 19-24.
43. Liu L, Ikonen S, Heikkinen T, Tapiola T, van Groen T, Tanila H. The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice. Exp Neurol 2002; 173 (2): 196-204.
44. Kogen H, Toda N, Tago K, Marumoto S, Takami K, Ori M, et al. Design and synthesis of dual inhibitors of acetylcholinesterase and serotonin transporter targeting potential agents for Alzheimer's disease. Org Lett 2002;4 (20): 3359-62.
45. Toda N, Tago K, Marumoto S, Takami K, Ori M, Yamada N, et al. Design, synthesis and structure-activity relationships of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorg Med Chem 2003; 11 (9): 1935-55.
46. Abe Y, Aoyagi A, Hara T, Abe K, Yamazaki R, Kumagae Y, et al. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. J Pharmacol Sci 2003; 93 (1): 95-105.
47. Sterling J, Herzig Y, Goren T, Finkelstein N, Lerner D, Goldenberg W, et al. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J Med Chem 2002; 45 (24): 5260-79.
48. Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999;366 (2-3): 127-35.
49. Weinstock M, Goren T, Youdim MB. Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with Cholinesterase and Monoamine Oxidase inhibitory activities. Drug Dev Res 2000; 50: 216-22.
50. Yogev-Falach M, Amit T, Bar-Am O, Weinstock M, Youdim MB. Involvement of MAP kinase in the regulation of annyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 2002; 16 (12): 1674-6.
51. Youdim MB, Amit T, Bar-Am O, Weinstock M, Yogev-Falach M. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Ann NY Acad Sci 2003; 993: 378-86; discussion 87-93.
52. Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27 (4): 555-61.
53. Alcala Mdel M, Vivas NM, Hospital S, Camps P, Muñoz-Torrero D, Badia A. Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids. Neuropharmacology 2003; 44 (6): 749-55.
54. Ishihara Y, Goto G, Miyamoto M. Central selective acetylcholinesterase inhibitor with neurotrophic activity: structure-activity relationships of TAK-147 and related compounds. Curr Med Chem 2000; 7 (3): 341-54.
55. Hirai K, Kato K, Nakayama T, Hayako H, Ishihara Y, Goto G, et al. Neurochemical effects of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3, 4, 5-tetrahydro-1H-1-b enzazepin-8-yl)-1-propanone fumarate (TAK-147), a novel acetylcholinesterase inhibitor, in rats. J Pharmacol Exp Ther 1997; 280 (3): 1261-9.
56. In t' Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345 (21): 1515-21.
57. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112 (3): 440-9.
58. Amitai G, Adani R, Rabinovitz I, Beit-Yanai E, Shohami E, Sod-Moriah G, et al. Bifunctional Compounds Eliciting both Antiinflammatory and Cholinergic Activity as Potential Drugs for CNS Disorders. Proceedings of the International Symposium on Cholinergic Synapse -Structure and Function. St. Moritz, Switzerland, 2002.
59. Reyes AE. Characterization of New Animal Models for the Study of Alzheimer's Disease. Faculty of Biological Sciences. Santiago: Pontifica Catholic University of Chile, 2000.
60. Hock BJ Jr, Lamb BT. Transgenic mouse models of Alzheimer's disease. Trends Genet 2001; 17 (10): S7-12.
61. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, et al. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997; 19 (4): 939-45.
62. Chacón MA, Reyes AE, Inestrosa NC. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioural deficits in mammalian hippocampus. J Neurochem 2003; 87 (1): 195-204.
63. Reyes A, Chacón M, Morgan C, Dinamarca M, Cerpa W, Inestrosa N. Acetylcholinesterase-Aβ complexes are more toxic than Aβ fibrils in rat hippocampus: Effect on rat β-amyloid aggregation, laminin expression, reactive astrocytosis and neuronal cell loss. Am J Pathol 2003; in press.
64. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39 (3): 409-21.
65. Mesulam MM. Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 1999; 24 (3): 521-9.
66. Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002; 5 Suppl: 1055-7.
67. Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. Annu Rev Cell Dev Biol 2002; 18: 25-51.
68. Soto C. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. Mol Med Today 1999; 5 (8): 343-50.
69. Morgan C, Bugueno MP, Garrido J, Inestrosa NC. Laminin affects polymerization, depolymerization and neurotoxicity of Abeta peptide. Peptides 2002; 23 (7): 1229-40.
70. Permanne B, Adessi C, Saborio GP, Fraga S, Frossard MJ, Van Dorpe J, et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J 2002; 16 (8): 860-2.
71. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6 (8): 916-9.
72. Steinberg D. Companies halt first Alzheimer vaccine trial. The Scientist. 2002; 16: 22-3.
73. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest 2003; 112 (3): 415-22.
74. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001; 8 (5): 890-9.
75. Yu QS, Zhu X, Holloway HW, Whittaker NF, Brossi A, Greig NH. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1, 2-oxazines. J Med Chem 2002; 45 (17): 3684-91.
76. De Ferrari GV. Structural Bases of the Interaction between Acetylcholinesterase and the Amyloid β-Peptide. Faculty of Biological Sciences. Santiago: Pontifica Catholic University of Chile, 2001; pp. 135.
77. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Design 2003; 9(6): 427-47.
78. Gualtieri F, Manetti D, Romanelli MN, Ghelardini C. Design and study of piracetam-like nootropics, controversial members of the problematic class of cognition-enhancing drugs. Curr Pharm Design 2002; 8(2): 125-38.
79. Schimmoller F, Higaki JN, Cordell B. Amyloid forming proteases: therapeutic targets for Alzheimer's disease. Curr Pharm Design 2002; 8(28): 2521-31.